Study design and treatments
The study design is described in Fig. VELIA study design. The primary objective of this study was to compare investigator-assessed progression-free survival for the veliparib-throughout arm versus control arm. As this was the primary objective of the study, data from the veliparib-throughout and control arms are included in this report. Secondary objectives included assessing safety. Pharmacokinetic parameters of veliparib were also evaluated.